SCHEMBL9848826

SCHEMBL9848826

CCN1CCN(CC)C(=O)C1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 2/20 0.39
PIK3CD O00329 1/20 0.38
GAA P10253 1/20 0.34
NPC1 O15118 2/20 0.33
GHSR Q92847 1/20 0.33
POLB P06746 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RAB9A P51151 1/20 0.33
MCHR1 Q99705 1/20 0.33
ALOX15 P16050 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
CHRNA7 P36544 1/20 0.32
PDE7B Q9NP56 1/20 0.32
BTK Q06187 1/20 0.32
MAPK1 P28482 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7902846 0.85 POLB (0.44) P2RX7PIK3CDNPC1POLBL3MBTL1
SCHEMBL772181 0.85 PIK3CD (0.35) P2RX7PIK3CDGAANPC1POLB
SCHEMBL7896130 0.85 POLB (0.44) P2RX7PIK3CDNPC1POLBL3MBTL1
SCHEMBL8826885 0.82 P2RX7 (0.38) P2RX7PIK3CDNPC1GHSRRAB9A
SCHEMBL21698479 0.82 ALOX15 (0.43) P2RX7PIK3CDNPC1GHSRPOLB
SCHEMBL23875186 0.82 ALOX15 (0.38) PIK3CDNPC1POLBL3MBTL1RAB9A
SCHEMBL26815162 0.82 PIK3CD (0.53) P2RX7PIK3CDNPC1POLBL3MBTL1
SCHEMBL24801766 0.82 KMT2A (0.41) PIK3CDNPC1POLBRAB9AMCHR1
SCHEMBL25023264 0.82 PLA2G2A (0.43) P2RX7PIK3CDNPC1POLBL3MBTL1
SCHEMBL24665502 0.81 P2RX7 (0.39) P2RX7PIK3CDGHSRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12584083-B2 Surface treatment composition, surface treatment method, and method for producing semiconductor substrate FUJIMI INCORPORATED (JP) 2026-03-24 US disclosed
US-20240124810-A1 SURFACE TREATMENT COMPOSITION, SURFACE TREATMENT METHOD, AND METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE FUJIMI INCORPORATED (JP) 2024-04-18 US disclosed
WO-2024081311-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-04-18 WO disclosed
WO-2023140146-A1 POLISHING COMPOSITION, CONCENTRATED SOLUTION OF POLISHING COMPOSITION, AND POLISHING METHOD 株式会社フジミインコーポレーテッド 2023-07-27 WO disclosed
CN-113179590-A Etching solution, replenishment solution, and method for forming copper wiring MEC股份有限公司 2021-07-27 CN disclosed
US-10174428-B2 Etchant, replenishment solution and method for forming copper wiring MEC COMPANY LTD. (JP) 2019-01-08 US disclosed
US-20170260632-A1 ETCHANT, REPLENISHMENT SOLUTION AND METHOD FOR FORMING COPPER WIRING MEC COMPANY LTD. (JP) 2017-09-14 US disclosed
WO-2017027684-A1 FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME ZAFGEN, INC. (US) 2017-02-16 WO disclosed
WO-2014113485-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2014-07-24 WO disclosed
US-20120165320-A1 NOVEL AZABICYCLOHEXANES PANACEA BIOTEC LTD. (IN) 2012-06-28 US disclosed
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF INOTEK PHARMACEUTICALS CORPORATION (US) 2010-10-14 US disclosed
US-7612075-B2 Substituted oxoazaheterocyclyl compounds AVENTIS PHARMACEUTICALS INC. (US) 2009-11-03 US disclosed
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors BLANCO MIGUEL GARCIA-GUZMAN 2009-09-24 US disclosed
US-7563795-B2 Phenyl-piperazine derivatives as modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-07-21 US disclosed
US-20070161647-A1 QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS GLAXOSMITHKLINE S.P.A. 2007-07-12 US disclosed
US-20070161647-A1 QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS GLAXOSMITHKLINE S.P.A. 2007-07-12 US disclosed
EP-0421794-A2 Preparation of piperazinones for use as sulfur dioxide absorbents THE DOW CHEMICAL COMPANY (US) 1991-04-10 EP disclosed
US-4980471-A Preparation of piperazinones for use as sulfur dioxide absorbents THE DOW CHEMICAL COMPANY (US) 1990-12-25 US disclosed
US-4767860-A Preparation of N-substituted piperazinones THE DOW CHEMICAL COMPANY (US) 1988-08-30 US disclosed
EP-0264261-A2 Preparation of N-substituted piperazinones THE DOW CHEMICAL COMPANY (US) 1988-04-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239873-A1 Phenyl-piperazine derivatives as modulators of muscarinic receptors CHRM3, CHRM5, CHRM2 P2RX7 228/4885PIK3CD 1830/4885GAA 3977/4885
US-20120165320-A1 NOVEL AZABICYCLOHEXANES CYP3A43, UGT1A1, CYP3A4 P2RX7 2068/4885PIK3CD 2320/4885GAA 1904/4885
US-20100261706-A1 SUBSTITUTED TETRACYCLIC 1H-INDENO [1,2-B]PYRIDINE-2(5H)-ONE ANALOGS THEREOF AND USES THEREOF TNNI3, TNNT2, ALDH1A2 P2RX7 476/4885PIK3CD 3015/4885GAA 3385/4885
US-12584083-B2 Surface treatment composition, surface treatment method, and method for producing semiconductor substrate PIEZO1, TYRO3, ACP1 P2RX7 280/4885PIK3CD 959/4885GAA 1676/4885
US-20070161647-A1 QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 and NK-2 RECEPTOR ANTAGONISTS KCNQ3, KCNK3, KCNK2 P2RX7 190/4885PIK3CD 1188/4885GAA 1364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.